{"name":"Lineage Cell Therapeutics, Inc.","slug":"lineage-cell-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AST-OPC1","genericName":"AST-OPC1","slug":"ast-opc1","indication":"Acute spinal cord injury","status":"phase_1"}]}],"pipeline":[{"name":"AST-OPC1","genericName":"AST-OPC1","slug":"ast-opc1","phase":"phase_1","mechanism":"AST-OPC1 is a human oligodendrocyte progenitor cell therapy that promotes myelination and repair in spinal cord injuries.","indications":["Acute spinal cord injury"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPNWw2SC1fc2EzUnlmeGotaWJ2MkNfempIZllBc1l6RmUtMWFNZjdRS2praVFDZnFPSnhMS09OQ0JvNUtDVUNUZWs5MlFWUk1aeVRkZVY1ZG9wM1VsWEt6THpPMEFYdGdIakpzUjRxSlV5b3lsc3BTLU8xbHAwajNLOWRRRi1VWVlKelMyVWFMb205clU?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Segmentation, Major Trends, and Competitive Overview of the Acute Spinal Cord Injury Market - openPR.com","headline":"Segmentation, Major Trends, and Competitive Overview of the Acute Spinal Cord Injury Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxPSkx5VHgxbGpTY0g1YXoyUDYwMDllbWxkd1pWZGZBYjJHbVhONUpXWHZMdDhrZ1RFRmxvZVAyVkRNUUUtZFFweGNUQXllby1IdnhkUkpZSUNRcmJIdlNaaEU1eGZHVFBjMmw2MlRlQ0t4NmpsWC1xQ18tUXNiU2RXMzN0amsyaG9UR1J1TnZJZTA3M3pjbjhuaG9KRVYwUWNyMlVnRjdRVFVwQkFUUUNNTEhhcE9VcXdvUHBud0plWERQZTAwOEJ4VjFEdFk4OEVud2tXY2tmRHA3TUJNVlc4cy1TXzVBQ3ZfbkpXc1FiTTlfME5SREJSemw0cGpwTExQTFhoWlFXYmpjcnRHOVk3ckR3czJvTEp5MU9aeFFkTk1ueE9vQ0k1NTd4MUJFNWRKVmdHM0tIek1PTk9mdV8xZ21ibDNHUTBYd0dpdGRTQUZvbUk?oc=5","date":"2026-03-30","type":"regulatory","source":"Barchart.com","summary":"Spinal Cord Injury Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development, Kessler - ","headline":"Spinal Cord Injury Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment By DelveInsig","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxQSzg1LUhmejlya1UyNHlEWDhzNndOWW9aS3Mwa1ozQmw1RkVEMGxPV056bmJXRUNkRzNGSmI1cTlMQTB0dmgxSElEWTJpYlJ5WGs2RXg5dEhuMzU3LVBUVmQwYVBTS3hPNlF6R2sxLVljeHY5SU9tRWRaME11SGlISjZENkNSMGpMR1hZc1hqaUNpSEpKeUx3VmdIZ1ZmWUtWcmk4TE9hbUpnMWhYQ1VybTMwcDU5LWVmNjZGdTF4dm50eFBHSk85TjEzc3hoVUpwdTlXazdacjlfN21tTmFEMGt2eWJ1YnJvNHVvN1ZB?oc=5","date":"2026-03-30","type":"trial","source":"Barchart.com","summary":"Hearing Loss Clinical Trial Pipeline Shows Potential with Active Contributions from 30+ Key Companies | DelveInsight - Barchart.com","headline":"Hearing Loss Clinical Trial Pipeline Shows Potential with Active Contributions from 30+ Key Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1IWGt0aHk5LV9Ra2l3Z2FqQXB5am1RODZZaVIydHJvM2ZMX2R6bFJ4R0VGWjAwU25CdkYzY1VocnAwcGpTcnJTNXhYVU9zanB6Sk5pbE9NVk1OMURLeHM3VEdkWGRlcnPSAWxBVV95cUxOV05WRWNUVmU1Zy1QRzNXQlBwQjlUb2xieU91ekx1SmNQcXEwQ2dxVkxtaThLd21uUzFiaE1pWEVZVVJ3dUQ1RjNTelpyb3hyLVlHa3ZyT3Y5c0ZTQUM2MFRaTFNEYkp2X2E0N3c?oc=5","date":"2026-03-05","type":"pipeline","source":"BioInformant","summary":"The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant","headline":"The Pipeline for iPSC-Derived Cell Therapeutics in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9CMVlELU04SWZQZ3FzWUVMdW8wMG9FV2dCU2RGVWp5cV9ldEFteEJRWkI5UFpsY2hKLV8xVHdxRXR3YjBuTFFXNld3RUgtZVlTdEFVZHFSNS1JWm1tWXU1bVR5ZGZEZzhqYm9keG50Ym5laEdkTUZTd05xSGJKMDQ?oc=5","date":"2026-01-30","type":"pipeline","source":"pharmaphorum","summary":"Allogeneic cell therapy isn’t dead, with Brian Culley - pharmaphorum","headline":"Allogeneic cell therapy isn’t dead, with Brian Culley","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOSDJkaHRVZzZLS0ZxSVp0bmN6VFpvQ0RiTEpqcGZIMjB3b3NvMkFFZ3hJRThxUF9JNkhGVkp0TGVpRkN3V1lEbVFTV1BUN0hRZ1Q5SVpXSEZlSUU0TTJoQTREa3k5TGxXY2VVaE96Y1E1NjYxMGVwZWMzTTYybXJDaVVkRkpNTnJWUnNVVFl4VHpveWpUaE1oY1ZrOHdIX3oySlB2WlNYanRvZnJSb2ZpazB3?oc=5","date":"2026-01-06","type":"pipeline","source":"Fierce Pharma","summary":"3 biopharma CEOs explain why they are 'authentically optimistic' for 2026 - Fierce Pharma","headline":"3 biopharma CEOs explain why they are 'authentically optimistic' for 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOUzczQWoxT2RTQkFnYzdDZEpIdnNsOGRVOVVUdjYxWEpRTFhZbm5MSXl6TW90WWhndFVMQmlGdklkT0VDSkR1RExIaGZiQ3Y5WE9qbi04X3RpSlNxbk8yWVNpVVBQYzRSbVlENWF5bVJnRnpubkxYTDBhSFJIQ05SU0RsNDM0b3lVcFJFZFluZ0dvNFBzWjNzVWtyWkxka1FGLWVDalhRdlJKMzFERVE?oc=5","date":"2025-11-13","type":"deal","source":"Seeking Alpha","summary":"Lineage Cell Therapeutics: OpRegen Makes It A Viable Speculative Buy - Seeking Alpha","headline":"Lineage Cell Therapeutics: OpRegen Makes It A Viable Speculative Buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxQWURYM1VhTm9mZGRBWU10OUhIYWNDRjhmYVJmSnJad3ZJeUxrTmk5R3hfQldBZmM1ajY2SzBtTnVlTVhfUEVJOU1FaVpMdFRwNjdHYnFmR1o3N1pVTW5PQm9Fblo1MEJONXd6eVk4VUxVczJMMDNwVkJyWTNtcTd6cTBLNDZpTHcxR29fRFpubHpjRzZjcldNaTRKRm1PUGtyTTJBMFNlSjhzWjY4N2pYSVRJTEZlQ2ozeXBBbHRZS0tNTTkxazg0LVZZX2Z6Y3l6OHZsbHhKZHF1aFZvZWRiRzdtWWNzeFVwaGFKbzh3cDh5UWhlSUdmQkhyeDEwTFFOUmZPLXFiMA?oc=5","date":"2025-10-30","type":"earnings","source":"businesswire.com","summary":"Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 - businesswire.com","headline":"Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxOMHFfWFg3czlEc21mZjRWSW05ZzlHcEIzOVJMRnF0cG9ZNjlIOXh5VDc3cy02VG5oazhKbHQ3MlBzUmd6VkhGR0kwb0wzVlNBYlBQVFJxa0MyRFVGVml6YzF0UlVOT2wydWd4RzhhNmZQY2o1UDJEUElOWjZZYlRxcHBjZ2s5TmJ5TkFILW03elY2UzA4UjJIMmNpQWx6WnpTT040RzF1QVV4X1R6Q2s5UVJqMXBYbW4wVEx4cGdTY2laWVpHWTF0bDdlV3UyVTNO?oc=5","date":"2025-09-08","type":"pipeline","source":"businesswire.com","summary":"Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes - businesswire.com","headline":"Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNLXJTdkFmMmlHSTgzM0J3NEpGUVpBUGlkeTNtQzV0T3NCdmZyUlpINmhZTWFrUTQyQ05KbmtLX0RNdUVMdHBiRldISHFXUzIyMVBCaDhRaVllLVBsbzBLb2w3NUFtSDlDWDZpcm1saER5ZjI2dlZvNHRuS053X3pJUmNrVmNqNTMxYUVIZGZkRmkzMUhLdldIZg?oc=5","date":"2025-09-08","type":"regulatory","source":"San Diego Business Journal","summary":"Lineage Nabs $12M Demant Partnership - San Diego Business Journal","headline":"Lineage Nabs $12M Demant Partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxQQ0x6dzdPV3hSWG5tLVhtT2ZxRVhuWTByUV9GMVg2QTV4MXhiQU1lbGNEVW9oOFRMUThFOEx6a3B2dEhmZS1kTFRLcHc1d0J1YjcyMjU1RXc4bE0zRk41dG9ac0E0cGZ0N1l3LW15ckh1emdNaTNUVHBXeVhuYWZGMUl3Z2UtVGVIa2EyUHo0LVowdHlWbzdkUHlUME9zTlhIYkY0a1BYSVJQT0gtOU1QNTdFQkxxcHBzLVo1bXVTUWhuMXRUbTkzVm9GUXpOWTE1aENJTzBScHIxNU1hWEU0NFAwaDhFeFRZU1Nr?oc=5","date":"2025-05-01","type":"earnings","source":"BioSpace","summary":"Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 - BioSpace","headline":"Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOS01qM0VETVRzRTRmUEpzcFZ1MU1qTTlGakozeEVVT0JxUmFibVdZbVg0QUNURkFLOE5GZnVRSDdwZ3V1cVZMVzI0RzZYNVlHX2lQV3dRdzdETEt3RVg4N2g2TlYxdURIci1DaEN6R3hxeHJHcUFmNUJ0YkJOS2szZHFfbk4tU2xMZE45UmVNNnlDcC0tT3BrZnBuUFhXcVNrZ1M2RnU0X2Y2VVBDRnVVY0xDQjRuSTg?oc=5","date":"2023-03-30","type":"pipeline","source":"Christopher & Dana Reeve Foundation","summary":"1st Annual Spinal Cord Injury Investor Symposium - Christopher & Dana Reeve Foundation","headline":"1st Annual Spinal Cord Injury Investor Symposium - Christopher & Dana Reeve Foundation","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}